South and Central America Neurological Biomarker Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product, Application, and End User

Published: April 6, 2021 |

The Insight Partners | 116 Pages | Delivery time: 1-2 business days

Price

Description
Table of Contents
List of Tables

Add to Compare

The South and Central America neurological biomarker market is expected to reach US$ 1,185.28 million by 2027 from US$ 502.07 million in 2019; it is estimated to grow at a CAGR of 11.5% from 2020 to 2027. The growth of the market is attributed to a few key driving factors such as rising prevalence of neurological diseases and growing focus on neurological biomarker research. On the other hand, concerns associated with the use of biomarkers such as the absence of pre-analytical tests are among the major factors that hinder the market growth.

Neurological biomarkers are molecules present in the cerebral spinal fluid (CSF) or blood that support the diagnosis of brain disorders and monitor disease progression. These biomarkers' primary sources are genetic mutations, metabolite levels, brain imaging, and changes in protein expression or post-translational modifications. This helps in the early detection of disease and less invasive diagnostics. It also allows faster drug development and is expected to be the effective treatment for neurological disorders. Currently, research activities focused on biomarkers in neurodegenerative diseases are significantly increasing due to the surging incidence of Alzheimer's and Parkinson's diseases across South and Central America. According to the latest report from Alzheimer's Disease International 2020, in Brazil, it was estimated that 6% of the 15 million people aged 60 years and above have Alzheimer's Disease. Also, the introduction of digital biomarkers and the growing focus on neurological biomarker research are anticipated to propel the growth of the South and Central America neurological biomarker market in the coming years.

The COVID-19 outbreak pandemic has adversely affected the countries in the South and Central America. Patients suffering from severe health conditions such as neurological diseases have been witnessing delays in chronic disease treatment. However, many companies and research institutes are taking initiatives to accelerate research in the diagnosis, treatment, and prevention of the neurological complications that may be caused by COVID-19. Thus, the South and Central America neurological biomarker market is facing challenges due to the COVID-19 outbreak.

The South and Central America neurological biomarker market, based on product, is segmented into proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker, and others. In 2019, the genomics biomarker segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest rate during the forecast period.

Based on application, the South and Central America neurological biomarker market is segmented into Alzheimer's disease, Parkinson's disease, schizophrenia, Huntington's disease, spinal muscular atrophy, and others. The Alzheimer's disease segment held the largest market share in 2019, and the market for the same segment is anticipated to grow at a significant rate during 2020 -2027.

The South and Central America neurological biomarker market, by end user, is segmented into pharmaceutical and biotechnology companies, clinical diagnostics, and research organizations. In 2019, the pharmaceutical and biotechnology companies segment held the largest share of the market. In addition, the market for the same segment is expected to grow at the fastest rate from 2020 to 2027.

A few of the primary and secondary sources referred to while preparing the report on the South and Central America neurological biomarker market are Alzheimer's Disease International (ADI), Brazilian Academy of Neurology, and Brazilian Institute of Neuroscience and Neurotechnology (BRAINN).

Reasons to Buy:

To understand the Middle East and Africa cell therapy instruments market landscape and identify market segments that are most likely to guarantee a strong return.

Stay ahead of the race by comprehending the ever-changing competitive landscape for the Middle East and Africa cell therapy instruments market.

Efficiently plan M&A and partnership deals in the Middle East and Africa cell therapy instruments market by identifying market segments with the most promising probable sales.

Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segments of the Middle East and Africa cell therapy instruments market.

Obtain market revenue forecast for market by various segments from 2019 to 2027 in Middle East and Africa.

Product Code: TIPRE00020960

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 South and Central America Neurological Biomarker Market - By Product
- 1.3.2 South and Central America Neurological Biomarker Market - By Application
- 1.3.3 South and Central America Neurological Biomarker Market - By End User
- 1.3.4 South and Central America Neurological Biomarker Market - By Country

2. Neurological Biomarker Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Neurological Biomarker Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 South & Central America
4.3 Expert Opinion

5. Neurological Biomarker Market - Key Market Dynamics

5.1 Key Market Drivers
- 5.1.1 Rising Prevalence of Neurological Diseases
- 5.1.2 Growing Focus on Neurological Biomarker Research
5.2 Key Market Restraints
- 5.2.1 Concerns Associated with Biomarkers
5.3 Key Market Opportunities
- 5.3.1 Increasing Awareness of Neurological Diseases Coupled with Developing Healthcare Infrastructure
5.4 Future Trends
- 5.4.1 The Rising Trend of Precision/Personalized Healthcare
5.5 Impact analysis

6. Neurological Biomarker Market - South and Central America Analysis

6.1 South and Central America Neurological Biomarker Market Revenue Forecast and Analysis

7. Neurological Biomarker Market Analysis- by Product

7.1 Overview
7.2 Neurological Biomarker Market Share, By Product, 2019 & 2027 (%)
7.3 Proteomics Biomarker
- 7.3.1 Overview
- 7.3.2 Proteomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.4 Genomics Biomarker
- 7.4.1 Overview
- 7.4.2 Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Metabolomics Biomarker
- 7.5.1 Overview
- 7.5.2 Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Imaging Biomarker
- 7.6.1 Overview
- 7.6.2 Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others Market Revenue and Forecasts to 2027 (US$ Mn)

8. Neurological Biomarker Market Analysis- by Application

8.1 Overview
8.2 Neurological Biomarker Market Share, By Application, 2019 & 2027 (%)
8.3 Alzheimer's Disease
- 8.3.1 Overview
- 8.3.2 Alzheimer's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Parkinson's Disease
- 8.4.1 Overview
- 8.4.2 Parkinson's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Schizophrenia
- 8.5.1 Overview
- 8.5.2 Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Huntington's Disease
- 8.6.1 Overview
- 8.6.2 Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Spinal Muscular Atrophy
- 8.7.1 Overview
- 8.7.2 Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Others
- 8.8.1 Overview
- 8.8.2 Others Market Revenue and Forecasts to 2027 (US$ Mn)

9. Neurological Biomarker Market Analysis- by End User

9.1 Overview
9.2 Neurological Biomarker Market Share, By End User, 2019 & 2027 (%)
9.3 Pharmaceutical and Biotechnology Companies
- 9.3.1 Overview
- 9.3.2 Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Clinical Diagnostics
- 9.4.1 Overview
- 9.4.2 Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Research Organizations
- 9.5.1 Overview
- 9.5.2 Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)

10. Neurological Biomarker Market Analysis and Forecasts To 2027 - Geographical Analysis

10.1 South and Central America: Neurological Biomarker Market
- 10.1.1 Overview
- 10.1.2 South and Central America: Neurological Biomarker Market - Revenue and Forecast to 2027(US$ Million)
- 10.1.3 South and Central America: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
- 10.1.4 South and Central America: Neurological Biomarker Market, by Application, 2018-2027 (USD Million)
- 10.1.5 South and Central America: Neurological Biomarker Market, by End User, 2018-2027 (USD Million)
- 10.1.6 South and Central America: Neurological Biomarker Market, by Country, 2019 & 2027 (%)
- 10.1.7 Brazil: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
  - 10.1.7.1 Brazil: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
  - 10.1.7.2 Brazil: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
  - 10.1.7.3 Brazil: Neurological Biomarker Market, by Application, 2018-2027 (USD Million)
  - 10.1.7.4 Brazil: Neurological Biomarker Market, by End User, 2018-2027 (USD Million)
- 10.1.8 Argentina: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
  - 10.1.8.1 Argentina: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
  - 10.1.8.2 Argentina: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
  - 10.1.8.3 Argentina: Neurological Biomarker Market, by Application, 2018-2027 (USD Million)
  - 10.1.8.4 Argentina: Neurological Biomarker Market, by End User, 2018-2027 (USD Million)

11. Impact of COVID-19 Pandemic on South and Central America Neurological Biomarker Market

11.1 South and Central America: Impact Assessment of COVID-19 Pandemic

12. Company Profiles

12.1 Thermo Fisher Scientific Inc.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Abbott
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Bio-Rad Laboratories Inc.
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 QIAGEN
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Immunarray Pvt. Ltd.
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Quest Diagnostics Incorporated
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Perkin Elmer, Inc.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 MERCK KGaA
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments

13. Appendix

13.1 Glossary of Terms

List Of Tables

Table 1. South and Central America Neurological Biomarker Market, by Product - Revenue and Forecast to 2027(USD Million)
Table 2. South and Central America Neurological Biomarker Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 3. South and Central America Neurological Biomarker Market, by End User- Revenue and Forecast to 2027 (USD Million)
Table 4. Brazil Neurological Biomarker Market, by Product - Revenue and Forecast to 2027 (USD Million)
Table 5. Brazil Neurological Biomarker Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 6. Brazil Neurological Biomarker Market, by End User- Revenue and Forecast to 2027 (USD Million)
Table 7. Argentina Neurological Biomarker Market, by Product - Revenue and Forecast to 2027 (USD Million)
Table 8. Argentina Neurological Biomarker Market, by Application - Revenue and Forecast to 2027 (USD Million)
Table 9. Argentina Neurological Biomarker Market, by End User- Revenue and Forecast to 2027 (USD Million)
Table 10. Glossary of Terms, Neurological Biomarker Market

List Of Figures

Figure 1. Neurological Biomarker Market Segmentation
Figure 2. Neurological Biomarker Market - By Country
Figure 3. South and Central America Neurological Biomarker Market Overview
Figure 4. Genomic Biomarkers Segment Held Largest Share of Neurological Biomarker Market
Figure 5. South and Central America Neurological Biomarker Market- Leading Country Markets (US$ Million)
Figure 6. South & Central America PEST Analysis
Figure 7. Expert Opinion
Figure 8. Neurological Biomarker Market Impact Analysis of Driver and Restraint
Figure 9. South and Central America Neurological Biomarker Market - Revenue Forecast and Analysis - 2019- 2027
Figure 10. Neurological Biomarker Market Share, by Product, 2019 & 2027 (%)
Figure 11. Proteomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Neurological Biomarker Market Share, by Application, 2019 & 2027 (%)
Figure 17. Alzheimer's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Parkinson's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. Neurological Biomarker Market Share, by End User, 2019 & 2027 (%)
Figure 24. Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. South and Central America: Neurological Biomarker Market, by Key Country - Revenue (2019) (USD Million)
Figure 28. South and Central America Neurological Biomarker Market Revenue and Forecast to 2027 (USD Million)
Figure 29. South and Central America: Neurological Biomarker Market, by Country, 2019 & 2027 (%)
Figure 30. Brazil: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
Figure 31. Argentina: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
Figure 32. Impact of COVID-19 Pandemic in South and Central America Market